A new anti-fibrotic drug attenuates cardiac remodeling and systolic dysfunction following experimental myocardial infarction

International Journal of Cardiology

Volumn 168, Issue 2, 2013, Pages 1174-1185

  Zhang, Yuan ^a   Elsik, Maros ^b   Edgley, Amanda J ^a   Cox, Alison J ^a   Kompa, Andrew R ^b   Wang, Bing ^b   Tan, Christina Yan Ru ^a   Khong, Fay L ^a   Stapleton, David I ^a   Zammit, Steven ^c   Williams, Spencer J ^c   Gilbert, Richard E ^d   Krum, Henry ^b   Kelly, Darren J ^a,e  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e Fibrotech Therapeutics Pty Ltd   (Australia)

Author keywords

Fibrosis; FT011; Hypertrophy; Myocardial infarction; Systolic dysfunction

Indexed keywords

ANGIOTENSIN II; ANTIFIBROTIC AGENT; CARBOXYMETHYLCELLULOSE; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; DIMETHYL SULFOXIDE; FT 011; MESSENGER RNA; PROLINE; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; COLLAGEN SYNTHESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DISEASE MODEL; DRUG EFFICACY; ECHOCARDIOGRAPHY; FIBROBLAST; HEART CATHETERIZATION; HEART EJECTION FRACTION; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE CELL; HEART PRELOAD; HEART STROKE VOLUME; HISTOPATHOLOGY; IN SITU HYBRIDIZATION; IN VIVO STUDY; INHIBITION KINETICS; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTOLIC DYSFUNCTION; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT OUTCOME;

FIBROSIS; FT011; HYPERTROPHY; MYOCARDIAL INFARCTION; SYSTOLIC DYSFUNCTION;

ANIMALS; ANIMALS, NEWBORN; ANTIFIBRINOLYTIC AGENTS; BLOOD PRESSURE; CAFFEIC ACIDS; COLLAGEN; MALE; MYOCARDIAL INFARCTION; ORTHO-AMINOBENZOATES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; VENTRICULAR REMODELING;

EID: 84885303447     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.11.067     Document Type: Article

References (47)

1. Weber KT, Sun Y, Tyagi SC, Cleutjens JP. Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms. J Mol Cell Cardiol 1994;26:279-92.
2. Greenberg B,QuinonesMA, Koilpillai C, et al. Effects of long-termenalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation 1995;91:2573-81.
3. Groenning BA, Nilsson JC, Sondergaard L, Fritz-Hansen T, Larsson HB, Hildebrandt PR. Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol 2000;36:2072-80.
4. Tsutamoto T, Wada A, Maeda K, et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 2001;37:1228-33.
5. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales investigators. Circulation 2000;102:2700-6.
6. Lee KW, Everett THt, Rahmutula D, et al. Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation 2006;114:1703-12.
7. Martin J, Kelly DJ, Mifsud SA, et al. Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-beta. Cardiovasc Res 2005;65:694-701.
8. Kelly DJ, Zhang Y, Connelly K, et al. Tranilast attenuates diastolic dysfunction and structural injury in experimental diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 2007;293:H2860-9.
9. See F. Tranilast inhibits pathological collagen deposition, independent of haemodynamic alteration, following myocardial infarction in the rat. J Am Coll Cardiol 2002;39:128B.
10. See F, Kompa A, Martin J, Lewis DA, Krum H. Fibrosis as a therapeutic target postmyocardial infarction. Curr Pharm Des 2005;11:477-87.
11. Kelly DJ, Zhang Y, Gow R, Gilbert RE. Tranilast attenuates structural and functional aspects of renal injury in the remnant kidneymodel. J AmSoc Nephrol 2004;15:2619-29.
12. Holmes Jr DR, Savage M, LaBlanche JM, et al. Results of prevention of REStenosis with Tranilast and its outcomes (PRESTO) trial. Circulation 2002;106:1243-50.
13. Zammit SC, Cox AJ, GowRM, et al. Evaluation and optimization of antifibrotic activity of cinnamoyl anthranilates. Bioorg Med Chem Lett 2009;19:7003-6.
14. Zhang Y, Edgley AJ, Cox AJ, et al. FT011, a newanti-fibrotic drug, attenuates fibrosis and chronic heart failure in experimental diabetic cardiomyopathy. Eur J Heart Fail 2012;14(5):549-62.
15. See F, Thomas W, Way K, et al. p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat. J Am Coll Cardiol 2004;44:1679-89.
16. Tzanidis A, Hannan RD, Thomas WG, et al. Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res 2003;93: 246-53.
17. Phrommintikul A, Tran L, Kompa A, et al. Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction. Am J Physiol Heart Circ Physiol 2008;294:H1804-14.
18. Boyle AJ, Kelly DJ, Zhang Y, et al. Inhibition of protein kinase C reduces left ventricular fibrosis and dysfunction following myocardial infarction. J Mol Cell Cardiol 2005;39:213-21.
19. Boyle AJ, Kelly DJ, Zhang Y, et al. Inhibition of protein kinase C reduces left ventricular fibrosis and dysfunction following myocardial infarction. J Mol Cell Cardiol 2005;39:213-21.
20. Schiller NB, Shah PM, CrawfordM, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358-67.
21. Connelly KA, Kelly DJ, Zhang Y, et al. Functional, structural and molecular aspects of diastolic heart failure in the diabetic (mRen-2)27 rat. Cardiovasc Res 2007;76: 280-91.
22. Hoit BD, Khan ZU, Pawloski-Dahm CM, Walsh RA. In vivo determination of left ventricular wall stress-shortening relationship in normal mice. Am J Physiol 1997;272:H1047-52.
23. Hoit BD,Walsh RA. In vivo echocardiographic assessment of left ventricular function in transgenic and gene-targeted mice. Trends Cardiovasc Med 1997;7:129-34.
24. Georgakopoulos D, Mitzner WA, Chen CH, et al. In vivo murine left ventricular pressure-volume relations by miniaturized conductance micromanometry. Am J Physiol 1998;274:H1416-22.
25. Saito T, Rodger IW, Hu F, Robinson R, Huynh T, Giaid A. Inhibition of COX pathway in experimental myocardial infarction. J Mol Cell Cardiol 2004;37:71-7.
26. Fiordaliso F, Bianchi R, Staszewsky L, et al. Antioxidant treatment attenuates hyperglycemia-induced cardiomyocyte death in rats. J Mol Cell Cardiol 2004;37: 959-68.
27. Martin JH, Connelly KA, Boyle A, et al. Effect of atorvastatin on cardiac remodelling and mortality in rats following hyperglycemia and myocardial infarction. Int J Cardiol 2010 Sep 3;143(3):353-60.
28. Lehr HA, Mankoff DA, Corwin D, Santeusanio G, Gown AM. Application of photoshop-based image analysis to quantification of hormone receptor expression in breast cancer. J Histochem Cytochem 1997;45:1559-65.
29. Lehr HA, van der Loos CM, Teeling P, Gown AM. Complete chromogen separation and analysis in double immunohistochemical stains using photoshop-based image analysis. J Histochem Cytochem 1999;47:119-26.
30. Gilbert RE, Cox A,Wu LL, et al. Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition. Diabetes 1998;47:414-22.
31. Baskin DG, Stahl W. Fundamentals of quantitative autoradiography by computer densitometry for in situ hybridization with emphasis on 33P. J Histochem Cytochem 1993;41:1767-73.
32. QiW, Chen X, Twigg S, Polhill TS, Gilbert RE, Pollock CA. Tranilast attenuates connective tissue growth factor-induced extracellular matrix accumulation in renal cells. Kidney Int 2006;69:989-95.
33. Thomas WG, Brandenburger Y, Autelitano DJ, Pham T, Qian H, Hannan RD. Adenoviral-directed expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor. Circ Res 2002;90:135-42.
34. Wilson CG, Stone JW, Fowlkes V, et al. Age-dependent expression of collagen receptors and deformation of type I collagen substrates by rat cardiac fibroblasts. Microsc Microanal 2011;17:555-62.
35. Agnoletti G, Cargnoni A, Agnoletti L, et al. Experimental ischemic cardiomyopathy: insights into remodeling, physiological adaptation, and humoral response. Ann Clin Lab Sci 2006;36:333-40.
36. Yang B, Larson DF, Beischel J, Kelly R, Shi J, Watson RR. Validation of conductance catheter system for quantification of murine pressure-volume loops. J Invest Surg 2001;14:341-55.
37. Richer C, Fornes P, Cazaubon C, Domergue V, Nisato D, Giudicelli JF. Effects of long-term angiotensin II AT1 receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats. Cardiovasc Res 1999;41:100-8.
38. Sun Y, Weber KT. Infarct scar: a dynamic tissue. Cardiovasc Res 2000;46:250-6.
39. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 1999;79:215-62.
40. Solomon SD, Pfeffer MA. Renin-angiotensin system and cardiac rupture after myocardial infarction. Circulation 2002;106:2167-9.
41. Fliss H, Gattinger D. Apoptosis in ischemic and reperfused rat myocardium. Circ Res 1996;79:949-56.
42. Kajstura J, Cheng W, Reiss K, et al. Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab Invest 1996;74: 86-107.
43. Sun Y, Weber KT. Cardiac remodelling by fibrous tissue: role of local factors and circulating hormones. Ann Med 1998;30(Suppl. 1):3-8.
44. Schiffer M, von Gersdorff G, Bitzer M, Susztak K, Bottinger EP. Smad proteins and transforming growth factor-beta signaling. Kidney Int Suppl 2000;77:S45-52.
45. Massague J, Chen YG. Controlling TGF-beta signaling. Genes Dev 2000;14: 627-44.
46. Yamaguchi Y, Mann DM, Ruoslahti E. Negative regulation of transforming growth factor-β by the proteoglycan decorin. Nature 1990;346:281-4.
47. O'Connor-McCourt MD, Wakefield LM. Latent transforming growth factor β in serum. J Biol Chem 1987;262:14090-9.